Patients are being paid to start hep C treatment — is it ethical?
Professor Thomas Snelling's team is targeting hard-to-reach patients who are yet to start direct-acting antivirals.
Since direct-acting antivirals were listed on the PBS seven years ago, more than 100,000 Australians have been cured of hepatitis C infection.
Yet this figure — a major accomplishment by any measure — only represents about half of those living with hepatitis C.
